MASTL is a potential poor prognostic indicator in ER+ breast cancer.
Year: 2017
Type: article
Source: PubMed
Authors: B-Z Zhuge, B-R Du, X-L Meng, Y-Q Zhang
Institution: Linyi People's Hospital
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3025917468